Actinogen Medical Receive Positive Results from Phase I Study & Begin Phase II Study

Actinogen Medical is focused on the treatment of Alzheimer’s disease. The lead drug candidate Xanamem™, blocks the production of excess cortisol (the stress hormone), which is associated with cognitive impairment and the development of amyloid plaques and neurodegeration in the brain – the hallmarks of Alzheimer’s disease.

In 2015, ACW successfully demonstrated positive results from a Phase I study including that Xanamem™ efficiently crosses the blood-brain-barrier in concentrations adequate to inhibit the production of excess cortisol in the brain. Actinogen is now conducting a Phase II study in mild Alzheimer’s disease patients. Alzheimer’s disease is a multibillion-dollar market in desperate need of new treatment options.

The results from the Phase II study, if positive, will likely generate substantial investment or acquisition interest from major pharmaceutical players.

ABOUT ACTINOGEN MEDICAL 

Actinogen Medical Ltd (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.

Actinogen is developing Xanamem™ as a novel treatment approach to Alzheimer’s disease and other age-related neurodegenerative diseases. Xanamem™ displays high potency and selectivity for inhibiting the activity of a key enzyme in the brain, which converts cortisone to cortisol. Cortisol is also known as the stress hormone, and elevated levels of cortisol has previously been linked to cognitive impairment.  The pivotal human proof of concept study, also known as XanADu, commenced in 2Q2016.